2019 American Transplant Congress
Slowed Progression of Maximal Intimal Thickening by Intravascular Ultrasound after Initiation of Sirolimus
1Children's Hospital Colorado, Aurora, CO, 2University of Florida Health, Gainesville, FL
*Purpose: Evidence in adult heart transplant (HT) patients (pt) shows that initiating sirolimus (SRL) slows progression of cardiac allograft vasculopathy (CAV) measured by intravascular ultrasound…2019 American Transplant Congress
Clinical Outcomes of Using mTOR Inhibitors with Reduced Dose of Calcineurin Inhibitors in Lung Transplant Recipients: A Single Center Experience
*Purpose: The use of mammalian target of rapamycin inhibitors (mTORi) in cardiothoracic transplantation has significantly increased over the past decade. Several recent clinical trials have…2019 American Transplant Congress
mTOR Inhibitors Associated with Higher Cardiovascular Adverse Events – A Large Population Database Analysis
*Purpose: Our study aimed to compare the adverse events (AEs) of tacrolimus to mammalian target of rapamycin (mTOR) inhibitors in solid organ transplant patients.*Methods: Our…2019 American Transplant Congress
Impact of Everolimus Therapy on HIV Persistence and Gene Expression in Transplant Patients
1UC San Francisco, San Francisco, CA, 2Case Western Reserve University, Cleveland, OH
*Purpose: mTOR is a key regulatory kinase that controls cell-cycle progression. mTOR inhibitors have been shown to reduce expression of CCR5 and promote viral transcriptional…2019 American Transplant Congress
Comparative Use of Single mTOR vs Dual mTOR/PI3K Inhibition in Regulatory T Cell Expansion for Clinical Application in Transplantation
University of Kentucky, Lexington, KY
*Purpose: Experimental and pre-clinical evidence suggest that adoptive transfer of regulatory T cells (Tregs) could be an appropriate therapeutic strategy to induce tolerance and improve…2018 American Transplant Congress
The Influence of a Conversion to Sirolimus-Based Immunosuppression on Non-Melanomatous Skin Cancer Incidence in Kidney Transplant Recipients over Long Term Follow Up
Background: The CONVERT trial found a reduced incidence of malignancy amongst renal transplant recipients over 2 years of follow up with a conversion from calcineurin…2018 American Transplant Congress
New Onset Diabetes after Kidney Transplant: Comparisons of Risks Associated with Various Steroid-Containing Calcineurin Inhibitor and Sirolimus Regimens
INTRODUCTION: We aimed to examine the risk of new onset diabetes after transplant (NODAT) associated with the following maintenance immunosuppression regimens in kidney transplant recipients…2018 American Transplant Congress
Incidence of Pneumonitis in Heart Transplant Patients Started on a Proliferation Signal Inhibitor
Cedars Sinai Medical Center, Los Angeles.
Purpose: Proliferation signal inhibitors(PSI) have a high discontinuation rate due to side effects. PSI induced pneumonitis has been reported in 14% in renal cell carcinoma…2018 American Transplant Congress
Early Conversion to a CNI-Free Immunosuppression with SRL after Renal Tx – 10 yr Follow-Up Analysis of a Prospective Multicenter Trial
Introduction: A prospective multicenter trial comparing an early conversion to a CNI-free immunosuppression with SRL, MMF and steroids with a conventional CsA treatment following renal…2018 American Transplant Congress
Sirolimus Use Improves Cancer-Free Survival Following Transplantation: A Single Center 10-Year Analysis
Introduction:In previous published results, we showed that the use of Sirolimus-based immunosuppression regimens had equivalent patient and graft 10-year survival compared to historical controls maintained…
American Transplant Congress abstracts